Celine Wilke

Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Fabrice André, Eva Ciruelos, Gábor Rubovszky et al. · New England Journal of Medicine · 2019 · 2.6K citations · Full text

Medicine, Oncology, Pharmacology +17

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

Robert Zeiser, Nikolas von Bubnoff, Jason Butler et al. · New England Journal of Medicine · 2020 · 865 citations · Full text

Medicine, Immunology, Pharmacotherapy +17

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Michael J. Morris, Daniel Castellano, Ken Herrmann et al. · The Lancet · 2024 · 258 citations · Full text

Medicine, Oncology, Urology +17

A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors

Jordi Rodón, Giuseppe Curigliano, Jean‐Pierre Delord et al. · Oncotarget · 2018 · 45 citations · Full text

Medicine, Oncology, Pharmacology +11

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer

Michail Ignatiadis, Dimitrios Zardavas, Marc Lemort et al. · PLoS ONE · 2016 · 39 citations · Full text

Medicine, Oncology, Pharmacology +17